Endogenous peptide hormone
Relaxin-2
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Relaxin-2 →Peptide directory
Find a peptide
Public profiles inside a larger governed registry
Search by peptide name, brand, or research code. Open a full evidence profile or the published sources available for a record still in development. Source publication does not mean a completed scientific appraisal.
The registry is an expanding catalog, not a complete list of every peptide. A missing public result does not mean no research exists.
Published profiles
Search profiles and sources
- Developing
Retatrutide (LY3437943) is an investigational long-acting peptide engineered to activate GIP, GLP-1, and glucagon receptors. Published early-phase and phase 2 studies report glycemic, body-weight, and liver-fat effects, but retatrutide has no FDA-approved indication. Gray-market products are not validated by these studies.
Evidence and record details
Evidence integrity map
Human 7Preclinical 0Durable IDs 27Open signals 2- Publication state
- Published profile
- Verified source records
- 25 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- 21 open research questions
- Evidence review date
- Documented human review recorded Sep 8, 2026
Source verification checks records; it does not itself approve scientific conclusions.
Endogenous RFamide peptide
RFamide-related peptide-1
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for RFamide-related peptide-1 →Endogenous RFamide peptide
RFamide-related peptide-3
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for RFamide-related peptide-3 →Synthetic tetrapeptide
Rigin
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Rigin →Cyclic depsipeptide therapeutic
Romidepsin
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Romidepsin →Research reference
RTD-1
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for RTD-1 →Research reference
RTD-2
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for RTD-2 →Calcitonin peptide
Salmon calcitonin
Published sources available; full evidence profile in development.
1 published source records. Source publication does not imply scientific appraisal.
Open sources for Salmon calcitonin →Endogenous bioactive peptide
Salusin-alpha
Published sources available; full evidence profile in development.
1 published source records. Source publication does not imply scientific appraisal.
Open sources for Salusin-alpha →Endogenous bioactive peptide
Salusin-beta
Published sources available; full evidence profile in development.
1 published source records. Source publication does not imply scientific appraisal.
Open sources for Salusin-beta →Research reference
Satoreotide tetraxetan
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Satoreotide tetraxetan →Research reference
Sauvagine
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Sauvagine →Scorpion-venom peptide
Scyllatoxin
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Scyllatoxin →Endogenous gastrointestinal peptide hormone
Secretin
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Secretin →- Emerging
Synthetic tuftsin-derived heptapeptide studied primarily in Russian-language preclinical and clinical literature.
Evidence and record details
Evidence integrity map
Human 0Preclinical 2Durable IDs 6Open signals 1- Publication state
- Published profile
- Verified source records
- 28 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- No open questions documented
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
- Substantial
Semaglutide is a long-acting analogue of human glucagon-like peptide-1 (GLP-1) engineered for resistance to DPP-4 degradation and prolonged albumin binding. It selectively activates the GLP-1 receptor. In humans, its pharmacologic effects include glucose-dependent stimulation of insulin secretion, reduced glucagon secretion, delayed gastric emptying, reduced calorie intake, and lower body weight. Clinical effects and approved uses depend on the formulation, indication, population, and regulatory jurisdiction; this archive separates those contexts rather than treating semaglutide as a single undifferentiated claim.
Evidence and record details
Evidence integrity map
Human 22Preclinical 1Durable IDs 25Open signals 3- Publication state
- Published profile
- Verified source records
- 25 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- 25 open research questions
- Evidence review date
- Documented human review recorded Sep 22, 2026
Source verification checks records; it does not itself approve scientific conclusions.
- Emerging
Synthetic ACTH-fragment-derived heptapeptide studied chiefly in Russian-language neurobiology and clinical literature.
Evidence and record details
Evidence integrity map
Human 0Preclinical 0Durable IDs 3Open signals 1- Publication state
- Published profile
- Verified source records
- 25 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- No open questions documented
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
How the public directory relates to the 500-record Master Registry
master registry transparency
500 master records, with governance status shown explicitly
501
Master records
467
Governed records
34
Review-deferred
458
Peptide acquisition eligible
9
Governed comparators
The master registry has 467 governed identities from 501 records. 34 remain review-gated. Nine governed records are scientific comparators, leaving 458 peptide identities in the source acquisition cohort. Database reconciliation is a separate step. The 51 profiles shown on this directory are a represented public-profile subset, not the size of the master registry. All 51 public profiles on this render reconcile to governed peptide identities in that registry; unknown, duplicate, deferred, or comparator identities fail closed instead of appearing publicly.
Explore the full Master Registry →What the profile status labels mean
Evidence, chemistry, and regulatory counts include only records that crossed the relevant public-publication gate. A zero means none published in that lane—not that nothing is known. “No governed record published” is a publication-state disclosure; internal or pending material may exist without appearing in public counts. Source verification, editorial publication, and accountable scientific appraisal are distinct states; a source count alone does not approve a scientific conclusion.
Recently updated public records
When each public profile record was last changed — not clinical or scientific activity.